Chembio Secures $5.7 Million Grant for Biothreat Detection Development

Chembio Diagnostic Systems, a subsidiary of BIOSYNEX SA, has been granted $5.7 million to further develop its DPP® Biothreat Panel. This grant is provided by the U.S. Biomedical Advanced Research and Development Authority (BARDA) and aims to enhance point-of-care diagnostics for critical biothreat pathogens.

The DPP® Biothreat Panel targets three significant pathogens: Yersinia pestis, Francisella tularensis, and Burkholderia pseudomallei. These pathogens cause diseases like plague and tularemia, necessitating quick and accurate identification, particularly in resource-limited settings.

Using the proprietary Dual Path Platform (DPP®) technology, Chembio plans to obtain FDA clearance for the assay. The project continues its BARDA-supported successes, previously tackling diseases like Zika and COVID-19.